Breaking News

Tweet TWEET

Apricus Biosciences Announces Management Changes

Apricus Biosciences Announces Management Changes

Bassam Damaj, Ph.D., to Step Down, Steve Martin, CFO, Appointed Interim CEO

SAN DIEGO, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com)
announced today that Bassam Damaj, Ph.D., has resigned as a Director,
President, and Chief Executive Officer of the Company and that Steve Martin,
Senior Vice President and Chief Financial Officer, has been appointed interim
Chief Executive Officer. The changes are effective immediately. The Company
also announced today that its Board of Directors has retained an executive
recruiting firm to assist in identifying a permanent Chief Executive Officer
whose experience is expected to include significant background in commercial
operations within the pharmaceutical industry.

Rusty Ray, Chairman of the Board, commented, "On behalf of the Apricus Bio
Board, I would like to thank Bassam for his leadership and contributions to
the Company, particularly during a challenging time in its history. We wish
him luck in his future endeavors. Apricus Bio is moving into a new chapter in
its development, one that will continue to be defined by global regulatory and
commercial milestones and success. It is the Board's goal to appoint a Chief
Executive who can help realize the significant value of our assets, including
Vitaros®, Femprox® and our NexACT® pipeline, during this important time."

Mr. Ray added: "We have confidence that Steve is both highly qualified and
experienced to serve as interim Chief Executive Officer, and the Board looks
forward to working closely with him and the senior management team during this
transition period."

Mr. Martin has served as Senior Vice President and Chief Financial Officer of
Apricus Bio since June 2011. He has over 25 years of experience in leadership
roles with significant expertise in growing public companies in a variety of
industries, including life sciences. Prior to joining Apricus Bio, Mr. Martin
was Senior Vice President and Chief Financial Officer of BakBone Software,
where he also served as interim CEO for a ten month period. Mr. Martin has
also served in senior positions at Stratagene Corporation, Gen-Probe
Incorporated and Deloitte & Touche. He was a former President and is a member
of the Board of Directors of Financial Executives International, San Diego
Chapter.

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, high-demand therapeutic classes. The Company has four approved
products and has developed a strong pipeline of multiple late-stage product
candidates. With commercial operations in both the U.S. and Europe (France),
Apricus Bio generates revenues and growth from sales of its commercial
products and by out-licensing, in certain territories, its pipeline products
and NexACT^® technology.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott and Bracco, and
co-promotes multiple products in France.

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.

For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Apricus logo